Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Marinus Pharmaceuticals

NASDAQ MRNS
$1.33 -0.05 -4.14%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

75.40M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
30.78M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.25
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
56.69M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-87.76 %

Upcoming events Marinus Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Marinus Pharmaceuticals

Stock analysis Marinus Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-0.53 8.79
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
4.50 25.38
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-0.24 4.40
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.34 0.50
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-842.52 9.54

Price change Marinus Pharmaceuticals per year

10.71$ 20.04$
Min Max

Summary analysis Marinus Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Marinus Pharmaceuticals

Revenue and net income Marinus Pharmaceuticals

All parameters

Stock news Marinus Pharmaceuticals

All news
19 September 2023 в 21:05

Marinus Pharmaceuticals Shares Rise 16% on Extended Cash Runway Into 4Q

19 September 2023 в 21:00

Marinus Pharmaceuticals Shares Rise 16% on Extended Cash Runway Into 4Q

26 May 2023 в 15:45

Marinus Pharmaceuticals Says CHMP Recommends EU Approval of Seizure Drug

26 May 2023 в 15:40

Marinus Pharmaceuticals Says CHMP Recommends EU Approval of Seizure Drug

12 May 2023 в 17:30

Marinus Pharmaceuticals price target cut to $42 from $50 at Truist Financial

21 March 2022 в 18:01

Marinus Pharmaceuticals Shares Drop 10% After 4Q Revenue Misses Expectations

21 March 2022 в 17:55

Marinus Pharmaceuticals Shares Drop 10% After 4Q Revenue Misses Expectations

18 March 2022 в 21:45

Marinus Pharmaceuticals Shares Up 14% on Drug Approval

23 February 2022 в 18:55

Marinus Pharmaceuticals Shares Drop 15% After Phase 3 Trial Delayed

23 February 2022 в 18:55

Marinus Pharmaceuticals Shares Drop 15% After Phase 3 Trial Delayed

18 August 2021 в 21:35

Marinus Pharmaceuticals Shares Down After Study Data

About company Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Address:
5 Radnor Corporate Center, Radnor, PA, United States, 19087
Company name: Marinus Pharmaceuticals
Issuer ticker: MRNS
ISIN: US56854Q2003
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2014-07-31
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.marinuspharma.com

On which stock exchange are Marinus Pharmaceuticals (MRNS) stocks traded?

Marinus Pharmaceuticals (MRNS) stocks are traded on NASDAQ.

What is the ticker of Marinus Pharmaceuticals stocks (MRNS)?

The stock ticker of Marinus Pharmaceuticals’s stocks or in other words, the code is MRNS. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Marinus Pharmaceuticals (MRNS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Marinus Pharmaceuticals (MRNS) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Marinus Pharmaceuticals (MRNS) stocks traded?

Marinus Pharmaceuticals (MRNS) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Marinus Pharmaceuticals (MRNS) stocks today?

The current price of Marinus Pharmaceuticals stocks on 14.05.2024 is 1.33 dollars. per share.

What is the dynamics of Marinus Pharmaceuticals (MRNS) stocks from the beginning of the year?

Marinus Pharmaceuticals (MRNS) quotes have increased by -87.21% from the beginning of the year up to 1.33 dollars. per 1 stocks.

How much did Marinus Pharmaceuticals (MRNS) stocks increase in мае 2024?

This month Marinus Pharmaceuticals (MRNS) quotes have increased by -9.52% to 1.33 dollars. per share.

How much are Marinus Pharmaceuticals (MRNS) stocks worth?

Today, on October, 14.05.2024 Marinus Pharmaceuticals’s (MRNS) stocks cost 1.33 dollars..

What is the market capitalization of Marinus Pharmaceuticals (MRNS)?

Capitalization is the market value of Marinus Pharmaceuticals (MRNS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 14.05.2024, the market capitalization of Marinus Pharmaceuticals (MRNS) is estimated at about 75395572 dollars.